BERKELEY, Calif., May 18, 2016 /PRNewswire/ -- Steep Hill, the industry leader in cannabis testing and analytics in the US and internationally, today announced it has licensed its cannabis testing technology to a highly-respected team of physicians with plans to open Steep Hill Maryland as a full service medical cannabis quality assurance laboratory in Baltimore, Maryland, bringing advanced scientific tools and methodology to the state.
In making the announcement, Steep Hill President and CEO Jmîchaeĺe Keller said, "We are pleased to announce our expansion to the East Coast, and Maryland in particular. We are especially proud of the highly qualified team of medical professionals leading our licensee partner in Maryland, and together we will deliver the best science, technology and professionalism available in cannabis testing for patients. This marks a new era in cannabis safety. The Maryland team consists of doctors, laboratory specialists and health care experts including board-certified pathologists, gastroenterologists, and highly experienced health care business professionals who have years of experience in patient care and testing human tissue to detect disease. We know this team will offer the highest standards to the patient community in Maryland and we are excited to announce this extremely qualified partnership."
Opening the new Maryland lab will be:
- Dr. Andrew Rosenstein, CEO of Steep Hill Maryland, and the Chief of the Division of Gastroenterology at University of Maryland Saint Joseph Medical Center. Dr. Rosenstein has been recognized by Baltimore Magazine as a top doctor in the Baltimore area and has an appointment as an Assistant Clinical Professor of Gastroenterology and Hepatology at the University of Maryland Medical Center.
- Dr. Charles J. Sailey, a board-certified clinical and Molecular Genetic Pathologist with medical licenses in several states. He has served as medical and scientific director of lab departments in molecular genetic pathology, molecular microbiology, metabolic genetics, toxicology, and clinical chemistry.
- Dr. Amin Khan, an experienced board-certified Gastroenterologist/Hepatologist who has been a Medical Director of a busy ambulatory endoscopy center, a co-founder of a human tissue diagnostics laboratory, and he is the principal founder and medical director of the innovative reference laboratory, Integrated Cellular and Molecular Diagnostics (ICMD).
- Mr. Marc Rosenstein, CPA, MBA, will serve as CFO, a capacity in which he has previously served healthcare systems, surgery centers, physician practices and pathology laboratories.
"We have worked very hard to establish our leadership in the cannabis testing space, and the strength of our new partners in Maryland is a testament to this leadership – together we intend to be the gold standard for science, service and safety for the medical cannabis industry in Maryland," said Keller.
For more information about cannabis testing, please visit the Steep Hill website: http://steephill.com
ABOUT STEEP HILL
Founded in California in 2008, Steep Hill Labs, Inc. is a science and technology firm that has become the industry leader in cannabis testing and analytics. With labs in five states—soon to be seven with Oregon and Maryland launching in 2016, along with a new facility in Jamaica—Steep Hill is the largest cannabis lab network in the world. The company pioneered the first medical cannabis potency and microbiological contaminants testing methodology for use in California—the first state to legalize medical cannabis. Steep Hill has since developed a variety of revolutionary cannabis testing products, including QuantaCann™, QuantaCann2™ and GenKit™. Steep Hill provides expert consulting services to many states, countries and municipalities, and the company is developing proprietary genetic testing, mapping and trademark protection services for the industry as well.
Cathie Bennett Warner
SOURCE Steep Hill Labs, Inc.